筛查时腺瘤检出率越高与长期结直肠癌发病率和死亡率越低相关
基于英国柔性乙状结肠镜筛查试验中167882名参与者中的40085名干预组人群,按各中心主要内镜医师的腺瘤检出率将中心分为高、中、低检出组,中位随访17年。高检出组较低检出组在远端和全部位结直肠癌发病率和死亡率上均观察到更大的筛查保护效应。
要点
- 高、中、低检出组平均腺瘤检出率分别为15%、12%、9%。
- 远端结直肠癌发病率:高检出组HR 0.34 vs 低检出组HR 0.55。
- 远端结直肠癌死亡率:高检出组HR 0.22 vs 低检出组HR 0.54。
核心结论
- 筛查时较高的腺瘤检出率对结直肠癌发病率和死亡率提供更大的长期保护。
研究设计与样本
- 英国柔性乙状结肠镜筛查试验中167882名参与者中的40085名干预组人群,在13个试验中心接受柔性乙状结肠镜筛查,中位随访17年。
- 采用多变量逻辑回归根据各中心主要内镜医师的腺瘤检出率将中心分为高、中、低检出组。
- 使用Cox回归估计远端和全部位结直肠癌发病率及死亡率的HR及95%CI。
主要发现
- 高、中、低检出组分别有5、4、4个中心,平均腺瘤检出率分别为15%、12%、9%。
- 远端结直肠癌发病率:高检出组HR 0.34(95%CI 0.27-0.42)vs 低检出组HR 0.55(95%CI 0.44-0.68)。
- 远端结直肠癌死亡率:高检出组HR 0.22(95%CI 0.13-0.37)vs 低检出组HR 0.54(95%CI 0.34-0.86)。
- 全部位结直肠癌发病率:高检出组HR 0.58(95%CI 0.50-0.67)vs 低检出组HR 0.72(95%CI 0.61-0.85),异质性未达统计学显著。
- 全部位结直肠癌死亡率:高检出组HR 0.52(95%CI 0.39-0.69)vs 低检出组HR 0.68(95%CI 0.51-0.92),异质性未达统计学显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Detection and removal of adenomas reduces colorectal cancer (CRC) risk. The impact of adenoma detection rates (ADRs) on long-term CRC incidence and mortality is unknown. We investigated this using data from the UK Flexible Sigmoidoscopy Screening Trial. METHODS: Of 167,882 UK Flexible Sigmoidoscopy Screening Trial participants, 40,085 were in the intervention arm and underwent flexible sigmoidoscopy screening at 13 trial centers. The median follow-up time was 17 years. At each center, 1 endoscopist performed most flexible sigmoidoscopies. Multivariable logistic regression was used to classify centers into high-, intermediate-, and low-detector groups based on their main endoscopist's ADR. We calculated the incidence and mortality of distal and all-site CRC, and estimated hazard ratios (HRs) with 95% CIs using Cox regression. RESULTS: Five, 4, and 4 centers, respectively, were classified into the high-detector, intermediate-detector, and low-detector groups. The average ADRs in each respective group were 15%, 12%, and 9%. Distal CRC incidence and mortality were reduced among those screened compared with controls in all groups, and effects of screening varied significantly by detector ranking, with larger reductions in incidence and mortality seen in the high-detector group (incidence: HR, 0.34; 95% CI, 0.27-0.42; mortality: HR, 0.22, 95% CI, 0.13-0.37) than in the low-detector group (incidence: HR, 0.55; 95% CI, 0.44-0.68; mortality: HR, 0.54; 95% CI, 0.34-0.86). Similar results were observed for all-site CRC, with larger effects seen in the high-detector (incidence: HR, 0.58; 95% CI, 0.50-0.67; mortality: HR, 0.52; 95% CI, 0.39-0.69) than in the low-detector group (incidence: HR, 0.72; 95% CI, 0.61-0.85; mortality: HR, 0.68; 95% CI, 0.51-0.92), although the heterogeneity was not statistically significant. CONCLUSIONS: Higher ADRs at screening provide greater long-term protection against CRC incidence and mortality. Isrctn.org, number: ISRCTN28352761.
引用
- Cross AJ, Robbins EC, Saunders BP, et al. Higher Adenoma Detection Rates at Screening Associated With Lower Long-Term Colorectal Cancer Incidence and Mortality. Clin Gastroenterol Hepatol. 2020. PMID: 32931959. doi:10.1016/j.cgh.2020.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。